Journal articles: 'Undenatured type II collagen (UC-II)'

1

Shavlovskaya, O. A., I. A. Bokova, I. D. Romanov, and N. I. Shavlovsky. "Efficacy of undenatured and hydrolyzed type II collagen in the treatment of pain syndrome." Russian Medical Inquiry 6, no. 10 (2022): 571–75. http://dx.doi.org/10.32364/2587-6821-2022-6-10-571-575.

Full text

Abstract:

Collagens play an important structural role and contribute to the mechanical properties, organization and shape of tissues. In musculoskeletal system diseases (MSD), the amount of type II collagen in the cartilage extracellular matrix significantly decreases. Degradation and reduction of type II collagen are associated with osteoarthritis (OA). At present, SYSADOA (Symptomatic Slow Acting Drugs for Osteoarthritis) are widely used in the treatment of OA for oral and parenteral use. Besides, increased attention has been paid to the new treatment methods for OA based on a new promising type II collagen molecule: undenatured (UC-II) and hydrolyzed (HC-II) collagen. UC-II is a native collagen (fibrillar protein with a molecular weight of 300 kDa), whereas HC-II is a polypeptide (molecular weight of 2–9 kDa). The article describes the molecular mechanisms of action of UC-II and HC-II, and identifies the main differences between them. The diverse mechanism of action of the described collagen types determines their clinical use: UC-II is prescribed mainly in MSD, in particular OA, and HC-II is mainly used in cosmetology, as well as in MSD. The article also presents the study results demonstrating the safety and efficacy of drugs and dietary supplements containing UC-II and HC-II in relieving pain syndrome during OA. KEYWORDS: undenatured type II collagen native collagen, hydrolyzed collagen, collagen peptides, SYSADOA, pain syndrome, osteoarthritis. FOR CITATION: Shavlovskaya O.A., Bokova I.A., Romanov I.D., Shavlovsky N.I. Efficacy of undenatured and hydrolyzed type II collagen in the treatment of pain syndrome. Russian Medical Inquiry. 2022;6(10):571–575 (in Russ.). DOI: 10.32364/2587-6821-2022-6-10-571-575.

APA, Harvard, Vancouver, ISO, and other styles

2

Juturu, Vijaya, George Pates, Robert Harris, Shane Durkee, and Zainulabedin Saiyed. "Recovery of Undenatured Collagen Type II from Different Prototypes of Food and Beverages Using Enzyme-Linked Immunosorbent Assay (ELISA)." Current Developments in Nutrition 5, Supplement_2 (2021): 327. http://dx.doi.org/10.1093/cdn/nzab037_037.

Full text

Abstract:

Abstract Objectives According to a new report in 2020, the global functional food market size is projected to reach USD 275.77 billion by 2025 at a CAGR of 7.9%. One of the major growth drivers for this includes increasing demand for nutritional and fortifying food additives. Undenatured type II collagen (UC-II®) is a dietary ingredient derived from chicken sternum and has been shown to improve joint health. The development of undenatured type II collagen in different food and beverage (F&B) products is gaining momentum. The objective of this study was to assess the compatibility and recovery of undenatured type II collagen from different prototypes of F&B. Methods A specific ELISA test that detects the presence of native type II collagen was used to measure undenatured type II collagen content. Results Results showed the recovery of undenatured type II collagen from the F&B matrices varied depending on the pH, pressure, humidity and processing temperature. Highest recovery was seen from F&B prototype of nutritional bars (∼100%), chews (98%), gummies (96%), and dairy beverage (81%). Conclusions In summary, the results from this study shows that UC-II® is able to withstand the processing conditions used for manufacturing F&B products. The applicability of this findings will allow UC-II® to be incorporated into different functional foods thereby helping the consumers to improve their joint mobility, flexibility and comfort. Funding Sources Lonza Consumer Health Ingredients Inc.

APA, Harvard, Vancouver, ISO, and other styles

3

Ekusheva, E. V., E. G. Zotkin, I. S. Dydykina, et al. "Review and resolution of the Council of Experts on the topic «The role of the combination of undenatured type II collagen UC-II, vitamin C, and trace elements in recovering and maintaining the function of the musculoskeletal system, and preservation of health of the joints»." Russian Journal of Preventive Medicine 28, no. 4 (2025): 102. https://doi.org/10.17116/profmed202528041102.

Full text

Abstract:

On October 6, 2024, the Council of Experts held a meeting to discuss «The role of the combination of undenatured type II collagen UC-II, vitamin C, and trace elements in recovering and maintaining the function of the musculoskeletal system and preservation of joint health.» New opportunities in preventing and treating osteoarthritis (OA), including in comorbid patients, are considered. Leading experts in rheumatology, clinical pharmacology, neurology, clinical immunology, orthopedics, traumatology, and sports medicine attended the meeting. The OA phenotypes, the mechanism of action of undenatured type II collagen, the data of clinical studies with undenatured collagen UC II, the integrative, interdisciplinary approach in the prevention and treatment of OA, and the prospects for using the VoltaFlex dietary supplement were analyzed. The resolution of the Council of Experts emphasized the importance of an integrated approach to the treatment of OA, including pharmacological and non-drug methods, and recommended using a combination of undenatured type II UC-II collagen, vitamin C, and trace elements to recover and maintain the musculoskeletal system’s function and preserve joint health.

APA, Harvard, Vancouver, ISO, and other styles

4

Rattanarat, Meechai. "A Literature Review of Undenatured type II collagen (UC-II) in Joint Health and Disease." International Journal of Current Science Research and Review 05, no. 10 (2022): 3818–21. https://doi.org/10.5281/zenodo.7139629.

Full text

Abstract:

ABSTRACT: Undenatured type II collagen (UC-II) is supplementary which is from chicken sternum cartilage. (Lugo, J. P., Saiyed,…,2015) UC-II has undenatured type II collagen componentand. The safety and capability of UC-II in adjusting joint discomfort in Osteoarthritis and Rheumatoid arthritis support by previous preclinical and clinical studies. (Lugo, J. P., Saiyed,…,2013) Osteoarthritis (OA) is atrophy joint disease affecting the quality of life of the elderly population. A lot of evidence that nutraceuticals from natural herbs may play essential part in inflammation and joint catastrophe in OA. Moreover, various studies these supplements have been found to be proficient in OA. None of these supplements have reported side effects. However, questions connected to their capability and safety for OA prevention and treatment is quality trials are needed to give absolute answers. (Vaishya, R., Agarwal,…,2018)

APA, Harvard, Vancouver, ISO, and other styles

5

Varney, Jessica L., Jason W. Fowler, and Craig N. Coon. "PSVI-33 Undenatured type II collagen mitigates inflammation and cartilage degeneration in healthy untrained Labrador retrievers after exercise." Journal of Animal Science 98, Supplement_4 (2020): 313–14. http://dx.doi.org/10.1093/jas/skaa278.559.

Full text

Abstract:

Abstract Exercise can cause microtrauma in the tissue and joints of dogs, resulting in a cycle of inflammation and discomfort even in healthy dogs. The aim of this trial was to evaluate the effect of undenatured type II collagen supplemented on inflammation and cartilage degeneration after exercise in untrained, healthy dogs. In this experiment, 40 healthy Labrador retrievers (20m/20f; Range-5-12yrs; Avg-8yrs) were sorted into two groups: undenatured type II collagen group receiving 40mg UC-II® (10mg Collagen Type II/Min. 3% Undenatured Type II Collagen; Lonza Consumer Health, Inc.) and placebo (P) group receiving 40mg maltodextrin daily by capsule. After 2wks supplement loading, all dogs performed a 4.66 ± 0.34km endurance run. Blood was collected at baseline, 1h pre-run, and 24h post-run for hematology/biomarkers including interleukin-6 (IL-6) as an inflammatory marker and cartilage oligomeric matrix protein (COMP) as a cartilage degeneration marker. Undenatured type II collagen supplemented dogs had significantly lower IL-6 vs P at post-run (p&lt; 0.01), as well as significant decreases from pre to post-run (P = 0.03), vs P with no significant change (P = 0.16). COMP was significantly lower in undenatured type II collagen supplemented dogs at 24h post-run compared to pre-run (P = 0.02), with P dogs having no significant differences between timepoints (P = 0.24). At both 1h pre- and 24h post-run undenatured type II collagen supplemented dogs had no significant increases in neutrophil:lymphocyte ratio (NLR; inflammatory marker), but P dogs had significantly higher NLR compared to baseline (P = 0.01). NLR was also significantly lower in undenatured type II collagen supplemented dogs compared to P dogs at pre-run (P &lt; 0.01). Undenatured type II collagen supplemented dogs showed significantly lower white blood cell counts after supplementation compared to P dogs (P &lt; 0.05) (Table 1). In summary, untrained Labrador retrievers supplemented with undenatured type II collagen had decreased inflammation and cartilage degeneration compared to non-supplemented dogs after exercise.

APA, Harvard, Vancouver, ISO, and other styles

6

Gromova, O. A., I. Yu Torshin, A. M. Lila, and O. A. Shavlovskaya. "On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases." Modern Rheumatology Journal 16, no. 4 (2022): 111–16. http://dx.doi.org/10.14412/1996-7012-2022-4-111-116.

Full text

Abstract:

Standardized extracts of undenatured type II collagen (UC-II) are used as alternative approaches to the treatment of osteoarthritis (OA). The effect of UC-II extracts is associated with the modulation of the mechanisms of innate and acquired immunity, a decrease in the activity of proinflammatory cytokines and prostaglandins. Epitopes of native collagen in the structure of UC-II contribute to a decrease in the activity of autoimmune reactions that stimulate cartilage degradation. Interacting with discoidin receptors, UC-II accelerates the reconstruction of cartilage connective tissue and inhibits the pro-inflammatory effects of endogenous collagens. Experimental and clinical studies confirm the effectiveness of the use of standardized substances UC-II for acceleration of cartilage regeneration and reduce pain in OA and subclinical joint dysfunction.

APA, Harvard, Vancouver, ISO, and other styles

7

Lau, Francis, Debasis Bagchi, and Siba Raychaudhuri. "Undenatured Type II Collagen (UC-II) in the Treatment of Osteoarthritis." Clinical Immunology 135 (January 2010): S99. http://dx.doi.org/10.1016/j.clim.2010.03.298.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fernández-Jaén, Tomás F., Carlos González de Vega, Paula Saiz, et al. "Pain reduction and tolerance of type II undenatured collagen in patients with knee osteoarthritis." International Journal of Research in Orthopaedics 9, no. 5 (2023): 900–907. http://dx.doi.org/10.18203/issn.2455-4510.intjresorthop20232607.

Full text

Abstract:

Background: Osteoarthritis (OA) is the most common cause of pain and disability in adults. Dietary supplements such as undenatured type II collagen (UC-II) have shown to have some benefits in OA treatment. This study aimed to assess changes in pain levels among knee OA patients treated with UC-II for 6 months. Methods: Patients with knee OA of any grade were given a daily 40 mg dose of UC-II (CondroArtil®) as a dietary supplement for 6 months. Pain levels were measured using the visual analog scale (VAS) before starting UC-II 6 months thereafter. A total of 100 patients (62/38: male/female) with a mean age of 46.3±13.8 years participated in the study. Most patients (60%) had mild to moderate OA (grade I or II). Results: The UC-II supplementation was shown to significantly reduce pain levels (p<0.001) with a negative correlation between pain reduction and age (p=0.006) and BMI (p=0.049). The OA severity also affected pain reduction (p=0.011), with grade II OA experiencing higher pain levels. Previous physical therapy and food supplements had a significant impact on pain reduction (p=0.017 and p=0.012, respectively). Conclusions: The study suggests that UC-II is an effective treatment for reducing pain in patients with knee OA.

APA, Harvard, Vancouver, ISO, and other styles

9

Bagchi, Manashi, Andrea Stocker, Ryan Burke, et al. "Efficacy and safety of undenatured type II collagen (UC-II) in arthritic horses." Toxicology Letters 172 (October 2007): S223. http://dx.doi.org/10.1016/j.toxlet.2007.05.563.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tjandra, Oentarini, Shirly Gunawan, Johan Johan, Fia Fia Lie, Marcella Erwina Rumawas, and Agus Limarta. "Efficacy and Safety of Undenatured Type II Collagen in The Treatment of Osteoarthritis of The Knee: A Randomized, Double-blind, Placebo-controlled Trial." Indonesian Biomedical Journal 15, no. 3 (2023): 277–86. http://dx.doi.org/10.18585/inabj.v15i3.2348.

Full text

Abstract:

BACKGROUND: Available medication for pain and joint stiffness release in osteoarthritis (OA) often gives considerable side effects. Undenatured type II collagen (UC-II) has been considered as a treatment for OA for its ability to prevent the progress of articular cartilage damage. Hence, this study aimed to evaluate the efficacy and safety of UC-II in modulating knee joint function.METHODS: This was a randomized, double-blind, placebo-controlled study involving 102 OA subjects. Subjects were randomized into two groups: receiving an oral daily dose of 40 mg/day UC-II or placebo containing microcrystalline cellulose for 90 days. Efficacy was evaluated by using the Western Ontario McMaster Osteoarthritis Index (WOMAC), Lequesne’s Functional Index (LFI), and Visual Analogue Scale (VAS) score on day-1, -7, -30, -60, and -90. Safety was evaluated by assessing the adverse events (AEs) and abnormal laboratory findings.RESULTS: The WOMAC total score showed a significant difference between the UC-II group vs. the placebo group from day-7 (p<0.05) to day-90 (p<0.01). UC-II was more effective in reducing the WOMAC total scores by 81.6% compared to 19.2% in the placebo group after 90 days. The total LFI and VAS score was significantly reduced in subjects supplemented with UC-II compared to the placebo group (75.8% vs. 7.8%; 67.9% vs. 12.2%, respectively). No significant changes were observed in vital signs and clinical laboratory tests compared to the placebo. The UC-II had a good safety profile with no serious adverse events among participants.CONCLUSION: UC-II significantly improved the knee pain, stiffness, and functional mobility of OA patients and was well-tolerated.KEYWORDS: osteoarthritis, undenatured type II collagen, WOMAC, VAS, LFI

APA, Harvard, Vancouver, ISO, and other styles

11

Shiojima, Yoshiaki, Hiroyoshi Moriyama, Megumi Takahashi, et al. "Novel ELISA technology in assessing undenatured type II collagen in functional foods and dietary supplements used for knee joint health care: its sensitivity, precision, and accuracy." Functional Foods in Health and Disease 12, no. 5 (2022): 234. http://dx.doi.org/10.31989/ffhd.v12i5.933.

Full text

Abstract:

Introduction: Undenatured type II collagen, derived from chicken sternum cartilage, is a novel functional ingredient, which has been demonstrated to improve joint health, flexibility and mobility, and enhancing motor functions. Undenatured type II collagen has been commercially available as functional dietary supplement worldwide for many years. Research studies demonstrated its broad-spectrum safety and clinical efficacy. Undenatured type II collagen requires very small amount to exhibit clinical efficacy and hence can be easily consumed over a long period of time as compared to the other joint care functional ingredients such as glucosamine and chondroitin. Since undenatured type II collagen is effective in relatively small amount, its accurate measurement in various dosage forms such as tablets and capsules become crucial to provide consumers optimal cost and joint-health benefits. Objective: In the present study, we modified the previously used Enzyme-Linked Immunosorbent Assay (ELISA) method to determine the active constituents precisely and accurately in formulations to affirm broad spectrum safety and clinical efficacy. Methods: Improved precision ELISA methodology was utilized to determine the amount of undenatured type II collagen extracted from chicken sternum cartilage. A commercially available Chondrex Collagen Detection Kit was used to determine the number of epitope (antigenic determinant) sites on the three-dimensional tightly-folded structured collagen. Time and temperature were set at ≥16 h or preferably within the range of 16 h to 24 h and at room temperatureResults: The results obtained from this improved ELISA method strongly supported the accuracy and validity, which correlates very well with the results of our earlier clinical studies, revealing the efficacy of undenatured type II collagen concentrations used. Furthermore, the modified ELISA method, designed by our team, revealed consistent and reproducible results on the basis of counting the epitope sites in undenatured type II collagen (NEXT-II®) of commercial batchesConclusion: Using this precisely modified ELISA method gave 8% of undenatured type II collagen in NEXT-II®, resulting in 3.2 mg in 40.0 mg of NEXT-II®. It also confirmed that administration of 3.2 mg of undenatured type II collagen a day, both in open-label and randomized clinical trials, was safe and efficacious for joint pain, flexibility and mobility, and motor function. Keywords: Undenatured type II collagen, NEXT-II®, ELISA method, Pepsin

APA, Harvard, Vancouver, ISO, and other styles

12

Kumar, Vivek, Udaybhan Maurya, Rajeev Gupta, et al. "GERI Study: Gathering Evidence and Real-World Insights in Osteoarthritis Management with Undenatured Type II Collagen." Journal of Orthopaedic Association of South Indian States 21, no. 2 (2024): 27–35. https://doi.org/10.4103/joasis.joasis_13_25.

Full text

Abstract:

Abstract Background: Osteoarthritis (OA) is a progressive joint disorder commonly affecting older adults and is increasingly prevalent in India. While conventional therapies offer symptomatic relief, they do not address the underlying disease process. Undenatured type II collagen (UC-II), a symptomatic slow-acting drug (SYSADOA), has emerged as a promising adjunct in OA management due to its ability to modulate immune response and improve joint function. Objective: The gathering evidence and real-world insights (GERI) study aimed to assess the knowledge, attitudes, and practices (KAP) of Indian orthopedic healthcare providers (HCPs) regarding the clinical use of UC-II in OA management. Materials and Methods: A cross-sectional, questionnaire-based study was conducted among 416 orthopedic HCPs across India. The survey evaluated OA prevalence, treatment strategies, UC-II efficacy and safety, and quality-of-life outcomes using structured KAP questionnaires. Results: The majority of HCPs (95.1%) favored collagen supplementation, with 61% preferring UC-II. Over 74% recommended UC-II alongside pharmacologic therapy. UC-II was most often initiated in early OA, with 60.2% reporting symptom improvement within one to three months. It was rated superior to glucosamine and chondroitin in adherence, efficacy, and tolerability. Additionally, 74.5% observed a reduction in nonsteroidal anti-inflammatory drug use. Physical therapy and weight management were the most commonly recommended adjuncts. Conclusion: The GERI study highlights strong clinical acceptance of UC-II among Indian orthopedic HCPs as an effective and well-tolerated adjunct in OA management. Its early use, combined with lifestyle interventions, may offer sustainable benefits in improving patient outcomes and reducing reliance on conventional drugs.

APA, Harvard, Vancouver, ISO, and other styles

13

Gencoglu, Hasan, Cemal Orhan, Emre Sahin, and Kazim Sahin. "Undenatured Type II Collagen (UC-II) in Joint Health and Disease: A Review on the Current Knowledge of Companion Animals." Animals 10, no. 4 (2020): 697. http://dx.doi.org/10.3390/ani10040697.

Full text

Abstract:

OA is quite common in companion animals, especially in large breed dogs and horses. Collagen, the most abundant protein of mammals, has specific connective tissue types for skin, bones, reticulate, basal lamina, bones, cell surfaces, while type II collagen (UC-II) forms the main structure of cartilage tissue. Even at the smaller dosages, UC-II has also been reported to be more effective than the glucosamine and chondroitin sulfate supplements, which are the supplements most frequently used in the market. In this review, we summarize the effects of UC-II on joint health and function in health and disease conditions in companion animals.

APA, Harvard, Vancouver, ISO, and other styles

14

Torshin, I. Yu, A. G. Chuchalin, and O. A. Gromova. "Oncoprotective effects of chondroprotectors: glucosamine, chondroitin sulfate and undenatured type II collagen." FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 16, no. 4 (2023): 681–99. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2023.182.

Full text

Abstract:

Objective: to systematize fundamental, clinical, and epidemiological data on the oncoprotective effects of chondroprotectors: chondroitin sulfate (CS), glucosamine (including glucosamine sulfate, GS), and undenatured type II collagen (UC-II).Material and methods. A systematic computer analysis of 6176 publications on the relationship between CS/GS/UC-II and tumor diseases found by the query “(glucosamine OR chondroitin OR ((“Collagen Type II” OR “type II collagen”) AND pharmacology)) AND (Cancer OR cancers OR tumor OR tumors OR tumors OR tumour*) NOT tumor necrosis)” in PubMed and Embase databases was performed. All articles of any format from 1900 to the present day with full available abstracts were taken. A topological approach to data analysis was used.Results. Large-scale clinical and epidemiological studies and meta-analyses showed that regular consumption of CS/GS reduced the risk of colorectal cancer and lung cancer, as well as mortality from tumor diseases. The mechanisms of oncoprotective action of CS/GS are through inhibition of the pro-inflammatory cascade of tumor necrosis factor alpha, CD44 receptor and nuclear factor kappa B, and initiation of tumor cell apoptosis. By modulating the CD44 receptor and specific O-glycosylation of intracellular proteins, GS inhibits the pro-inflammatory effects of arachidonic acid cascade, interleukins IL-6, IL-8, the PI3K/Akt proliferative pathway, and cyclin-dependent kinases. The first postgenomic studies of CS/GS oncoprotective effects, including microbiome studies, was performed. Additionally, CS contributes to the inhibition of the effects of vascular endothelial growth factor and matrix metalloproteinases involved in tumor metastasis and invasion. Potentially, CS/GS oncoprotective effects may be enhanced by the anti-inflammatory effect of UC-II: the addition of NC-II substance to CS/GS complex makes it possible to reduce the autoimmune branch of pathogenesis not only in primary, but also in secondary OA and rheumatoid arthritis.Conclusion. The CS and glucosamine (including GS) chondroprotectors exhibit oncoprotective effects. The use of CS and GS together with UС-II standardized pharmaceutical forms can enhance their anti-inflammatory and immunomodulatory effects.

APA, Harvard, Vancouver, ISO, and other styles

15

Yamin, Muhammad, and D. Henky Lesmana. "Pengaruh Bauran Pemasaran Terhadap Keputusan Peresepan Undenatured Type II Collagen Dalam Penatalaksanaan Osteoartritis Lutut." Farmasains : Jurnal Ilmiah Ilmu Kefarmasian 6, no. 2 (2019): 51–58. http://dx.doi.org/10.22236/farmasains.v6i2.3790.

Full text

Abstract:

Osteoartritis merupakan penyakit sendi yang paling sering dialami oleh manusia, terutama lutut. Osteoartritis lutut terjadi sekitar 15,5% pada pria dan 12,7% pada wanita di Indonesia. Adanya kebutuhan dan peluang pasar, maka dalam pemasaran produk Undenatured type-II collagen (UC-II) yang sedang dikembangkan, perlu dianalisis bauran pemasaran apa yang paling berpengaruh. Tujuan penelitian ini adalah melakukan studi pengaruh baruan pemasaran; seperti produk (X1), harga (X2), promosi (X3); terhadap keputusan peresepan UC-II dalam penatalaksanaan osteoarthritis lutut. Data dikumpulkan melalui kuisioner yang diuji di lapangan dengan metode non-probability-purposive yang diberikan kepada 20 sampel dokter spesialis bedah tulang, rematik, dan penyakit dalam yang berpraktik di Jakarta. Penelitian diawali dengan melakukan interview mendalam kepada responden dan dilanjutkan dengan metode kuantitatif. Berdasarkan uji F, hasil analisis menunjukkan nilai F=43,224 dengan signifikansi 0,000 dan R=0,744 yang mengindikasikan dampak kuat pada baruan pemasaran secara serempak. Demikian pula, hasil analisis uji T adalah ‘t’=3,995 (X1), 2,903 (X2), dan 2,413 (X3) dengan signifikansi <0,05 yang mengindikasikan dampak kuat pada baruan pemasaran secara individu. Berdasarkan hasil penelitian ini dapat disimpulkan bahwa terdapat pengaruh yang kuat antara baruan pemasaran (produk, harga, promosi) terhadap keputusan peresepan UC-II secara individu maupun serempak.

APA, Harvard, Vancouver, ISO, and other styles

16

Fan, Rui, Yuntao Hao, Xinran Liu, et al. "Undenatured Type II Collagen Relieves Bone Impairment through Improving Inflammation and Oxidative Stress in Ageing db/db Mice." Molecules 26, no. 16 (2021): 4942. http://dx.doi.org/10.3390/molecules26164942.

Full text

Abstract:

Ageing-related bone impairment due to exposure to hyperglycemic environment is scarcely researched. The aim was to confirm the improvement effects of undenatured type II collagen (UC II) on bone impairment in ageing db/db mice, and the ageing model was established by normal feeding for 48-week-old. Then, the ageing db/db mice were randomly assigned to UC II intervention, the ageing model, and the chondroitin sulfate + glucosamine hydrochloride control groups. After 12 weeks of treatment, femoral microarchitecture and biomechanical parameters were observed, biomarkers including bone metabolism, inflammatory cytokines, and oxidative stress were measured, and the gastrocnemius function and expressions of interleukin (IL) 1β, receptor activator of nuclear factor (NF)-κB ligand (RANKL), and tartrate-resistant acid phosphatase (TRAP) were analyzed. The results showed that the mice in the UC II intervention group showed significantly superior bone and gastrocnemius properties than those in the ageing model group, including bone mineral density (287.65 ± 72.77 vs. 186.97 ± 32.2 mg/cm3), gastrocnemius index (0.46 ± 0.07 vs. 0.18 ± 0.01%), muscle fiber diameter (0.0415 ± 0.005 vs. 0.0330 ± 0.002 mm), and cross-sectional area (0.0011 ± 0.00007 vs. 0.00038 ± 0.00004 mm2). The UC II intervention elevated bone mineralization and formation and decreased bone resorption, inflammatory cytokines, and the oxidative stress. In addition, lower protein expression of IL-1β, RANKL, and TRAP in the UC II intervention group was observed. These findings suggested that UC II improved bones impaired by T2DM during ageing, and the likely mechanism was partly due to inhibition of inflammation and oxidative stress.

APA, Harvard, Vancouver, ISO, and other styles

17

Prabhoo, Ram, and Gauri Billa. "Undenatured collagen type II for the treatment of osteoarthritis: a review." International Journal of Research in Orthopaedics 4, no. 5 (2018): 684. http://dx.doi.org/10.18203/issn.2455-4510.intjresorthop20183386.

Full text

Abstract:

Osteoarthritis is a prevalent musculoskeletal condition worldwide with rising rates in elderly people. Both mechanical and immunological factors are implicated in the pathogenesis of osteoarthritis resulting in destruction of the articular cartilage. Non-steroidal anti-inflammatory drugs (NSAIDs) commonly used for the treatment of osteoarthritis, are associated with several adverse events and also do not affect the underlying disease process. Clinicians and patients both seek options which are safe and effective in the treatment of osteoarthritis. Collagen derivatives represent a suitable option in such cases. Collagen is the most abundant component of the cartilage. Collage derivatives have shown to have disease modifying action in osteoarthritis. Depending on the degree of hydrolysis and molecular weight, collage derivatives are classified into undenaured collagen, gelatin and collage hydrolysate. Collagen derivatives are well tolerated without major safety concerns. Undenatured type II collagen has shown to provide significant improvement in patients with osteoarthritis. In this article we discuss, the pathophysiology of osteoarthritis with focus on immunological factors and evidence for the use of undenatured collagen type II in osteoarthritis.

APA, Harvard, Vancouver, ISO, and other styles

18

Alam, Md Mahbubul, Md Sakib Rayhan, Arnob Ghosh, and ASM Monjur Al Hossain. "A Cross-sectional Study on the Prescription Pattern of Undenatured Collagen-II in Bangladeshi Patients." Bangladesh Pharmaceutical Journal 26, no. 2 (2023): 157–61. http://dx.doi.org/10.3329/bpj.v26i2.67805.

Full text

Abstract:

Numerous clinical and experimental studies have shown that individuals with a variety of orthopedic diseases can get benefit from the undenatured form of type II collagen (UC-II). It has proved its efficacy and long lasting effectiveness for several orthopedic patients throughout different countries in the world. But in Bangladesh it is not frequently prescribed yet. Therefore, we made the decision to conduct a survey-based study to determine the number of patients prescribed with UC-II under which pathological conditions and to what extent they have got relief from their joint associated ailments. To conduct the study, we visited the orthopedic department of various hospitals in Bangladesh and with consent from patients we collected pictures of prescriptions as well as got overview regarding their complications. We gathered photographs of 252 prescriptions from orthopedic department patients, among which only 31 patients were prescribed with UC-II. According to this study, 40.47 , 32.54 , 15.47 , 9.12 and 2.38 % of patients were over the age group of 60 , 50 , 40 , 30 and 20 - years respectively. We found that a range of individuals with various orthopedic problems such as osteoarthritis, spondylosis, right tibial plateau, paresthesia in right upper limb and various bone fractures were advised with UC-II. However, we discovered only in 12.30% of prescriptions that the doctors prescribed UC-II, indicating this is a less common practice in Bangladesh in spite of its huge potential to recover joint pain associated complications. Bangladesh Pharmaceutical Journal 26(2): 157-161, 2023 (July)

APA, Harvard, Vancouver, ISO, and other styles

19

DEPARLE, L. A., R. C. GUPTA, T. D. CANERDY, et al. "Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogss." Journal of Veterinary Pharmacology and Therapeutics 28, no. 4 (2005): 385–90. http://dx.doi.org/10.1111/j.1365-2885.2005.00668.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Zapata, Ana, and Rocio Fernández-Parra. "Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata." Animals 13, no. 5 (2023): 870. http://dx.doi.org/10.3390/ani13050870.

Full text

Abstract:

In the multimodal management of osteoarthritis (OA) in recent decades, the use of feed supplements to maintain joint cartilage has been advocated. The aim of this scoping review is to present the results found in the veterinary literature on the use of undenatured type II collagen and Boswellia serrata in dogs, specifically its use in dogs with clinical signs of OA, healthy dogs after intense exercise or dogs with diseases that predispose the individual to OA. For this purpose, a literature review was carried out using the electronic databases PubMed, Web of Science and Google Scholar, from which a total of 26 records were included in this review: fourteen evaluating undenatured type II collagen, ten evaluating Boswellia serrata and two evaluating the combination of undenatured type II collagen and Boswellia serrata. The review of the records showed that undenatured type II collagen decreases the clinical signs associated with OA, improving the general clinical state with a reduction in the degree of lameness and increase in physical activity or mobility. Evaluating the response to supplementation with Boswellia serrata alone is complicated due to the limited publication of studies and variations in the purity and compositions of the products used, but in general terms, its combination with other feed supplements produces benefits by relieving pain and reducing the clinical signs of OA in dogs. The combination of both in the same product provides results similar to those obtained in undenatured type II collagen studies. In conclusion, undenatured type II collagen and Boswellia serrata are considered a valid option for the multimodal approach to the management of OA and for improving activity during intense exercise, but more studies are needed to conclude whether or not it prevents OA in dogs.

APA, Harvard, Vancouver, ISO, and other styles

21

Sahin, Kazim, Cemal Orhan, Mehmet Tuzcu, Nurhan Sahin, and Vijaya Juturu. "Effect of Marine Phytoplankton (Oceanix) and Undenatured Type II Collagen in Combination with Exercise on Endurance Capacity and Oxidative Stress in Rats." Current Developments in Nutrition 4, Supplement_2 (2020): 1764. http://dx.doi.org/10.1093/cdn/nzaa066_019.

Full text

Abstract:

Abstract Objectives To study the effect of exercise training alone and or in combination with marine phytoplankton (Oceanix, OCX) and undenatured type II collagen (UCII) supplementation on the endurance capacity, pro-inflammatory markers, and antioxidant defense markers in rats. Methods A total of 28 male Wistar albino rats were randomly divided into four groups (n = 7) (i) No exercise and no OCX (Control), (ii) Exercise, (iii) Exercise +OCX-I (2.55 mg d/rat) + UC-II (4 mg), iv) Exercise + OCX-2 (5.1 mg d/rat)+UC-II (4 mg). Levels of cholesterol, triglyceride, proinflammatory cytokines (IL-1β, IL-6, TNF-α, COMP, CRP), lactate and malondialdehyde (MDA) levels activities of antioxidant enzymes were determined in all the groups. Results Run to exhaustion (minutes) improved in the OCX + UC-II treated groups. Levels of cholesterol, triglyceride, proinflammatory cytokines (IL-1β, IL-6, TNF-α, COMP, CRP) decreased by OCX + UC-II supplementation. A significant decrease in lactate and malondialdehyde (MDA) levels and an increase in activities of antioxidant enzymes were observed in the combination of exercise and OCX + UC-II groups. Exercise + OCX + UC-II treated had lower TNF-α and IL-1β levels in muscle than exercise and control rats (P &lt; 0.001). Muscle sterol regulatory element-binding protein 1c (SREBP-1c), liver X receptors (LXR), ATP citrate lyase (ACLY) and fatty acid synthase (FAS) levels in the exercise + OCX + UC-II group were lower than all groups (P &lt; 0.05). The effectiveness of the high dose of OCX was more pronounced than the low dose of OCX. Conclusions These results suggest OCX and UC-II with exercise may enhance lipid metabolism by regulation of gene products involved in lipid and antioxidant metabolism including SREBP-1c, -γ, LXR, ACLY and FAS in rats. Funding Sources Lonza.

APA, Harvard, Vancouver, ISO, and other styles

22

Jain, Karun, Apurv A. Mehra, Kapil D. Mehta, Lyndon L. Dsouza, and Ratna Kumar. "Role of undenatured collagen type II and Aflapin combination in the management of osteoarthritis: a review." International Journal of Research in Orthopaedics 7, no. 4 (2021): 885. http://dx.doi.org/10.18203/issn.2455-4510.intjresorthop20212441.

Full text

Abstract:

Osteoarthritis (OA) is the most common joint disease affecting millions worldwide. Osteoarthritis typically affects the knees, hands, hips, and feet. It is characterized by complex pathologic changes in cartilage which haven’t been fully elucidated yet. However, recent research has shown the involvement of two contributing pathways namely the mechanical and the immune pathways which interlink to cause cartilage destruction. Patients with OA on current treatment options still inevitably progress to a more severe stage becoming candidates for total joint replacement. The cornerstones of OA management in the early stage include exercises, weight loss, education—complemented by topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs) and nutraceuticals like Undenatured type II collagen and Aflapin. Both Undenatured type II collagen and Aflapin offer great promise in OA management by targeting both the immune and mechanical pathways respectively. Undenatured type II collagen works by oral tolerization turning off the immune response in the inflammatory damage (T cell response) against endogenous Type II collagen in the cartilage thus reducing joint inflammation and degradation and stimulates anti-inflammatory cytokine release. Aflapin inhibits 5-LOX and exerts anti-inflammatory action thus providing symptomatic relief of pain and inflammation. This review focusses on the role of mechanical and immune pathways in the pathogenesis of OA and the impact of the combination of Undenatured type-II collagen and Aflapin in targeting these pathways thus improving the clinical outcomes.

APA, Harvard, Vancouver, ISO, and other styles

23

Stabile, Marzia, Rossella Samarelli, Paolo Trerotoli, et al. "Evaluation of the Effects of Undenatured Type II Collagen (UC-II) as Compared to Robenacoxib on the Mobility Impairment Induced by Osteoarthritis in Dogs." Veterinary Sciences 6, no. 3 (2019): 72. http://dx.doi.org/10.3390/vetsci6030072.

Full text

Abstract:

Osteoarthritis (OA) is a chronic disease that requires a multimodal therapeutic approach. The aim of this study was to evaluate the effects of undenatured type II collagen (UC-II) as compared to robenacoxib in dogs affected by OA. Our hypothesis was that the two compounds would be similar (non-inferiority) in improving mobility. To test this hypothesis, a complete orthopedic examination, x-ray and the Liverpool Osteoarthritis in Dogs (LOAD) survey were performed in dogs affected by OA before and after the treatments. The study was designed as a clinical, randomized, controlled and prospective study. Sixty client-owned dogs were randomized in the R group (n = 30, robenacoxib 1 mg/kg/day for 30 days) and in the UC-II group (n = 30, UC-II 1 tablet/day for 30 days). Thirty days after the beginning of the treatment (T30), the dogs were reassessed for the LOAD, MOBILITY and CLINICAL scores. Based on the data obtained from the study, a significant reduction in LOAD and MOBILITY scores was recorded between T0 and T30 with a similar magnitude among the two groups (R = 31.5%, p < 0.001; UC-II = 32.7%, p = 0.013). The results of this study showed that UC-II and robenacoxib were able to similarly improve mobility of dogs affected by OA.

APA, Harvard, Vancouver, ISO, and other styles

24

Rekalov, D., I. Golovach, I. Daniuk, R. Kulynych, T. Tarasenko, and I. Bryner. "AB1188 DYNAMICS OF PAIN SYNDROME DURING 180-DAY TREATMENT WITH UNDENATURED COLLAGEN TYPE II IN COMPARE TO GLUCOSAMINE AND CHONDROITIN COMBINATION." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1824.2–1824. http://dx.doi.org/10.1136/annrheumdis-2023-eular.655.

Full text

Abstract:

BackgroundOA osteoarthritis is a heterogeneous group of diseases of different etiology with similar biological, morphological, clinical manifestations and consequences, which are based on damage to all articular structures (cartilage, subchondral bone, synovial membrane, ligaments, capsules, periarticular muscles). A key role in the pathogenesis of OA is played by an increase in the catabolic activity of various cytokines, as well as matrix metalloproteinases (MMP) of the cartilage itself.ObjectivesThe purpose of the study was to compare the dynamics of pain syndrome (based on Western Ontario McMaster Osteoarthritis Index – WOMAC pain subscale) during 180-day treatment with undenatured collagen type II (UC-II) and glucosamine and chondroitin (G + Ch) combination in patients with Grade II knee OA.MethodsPatients with Grade II knee OA were investigated. 20 patients were administrated the UC-II during 180-day period, 20 patients took the combination of G + Ch during the same period. WOMAC pain subscale was used to evaluate the effectiveness and was completed before the start of therapy and after 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 90, 120, 150, 180 day of treatment. Visual analog scale (VAS) from 0 to 10 was used for assessment the WOMAC subscale by patient. In this abstract we presented the dynamics of pain during walking and nocturnal pain.ResultsThe initial data of pain during walking and nocturnal pain in UC-II group were 6.29±0.37 and 4.35±0.59, after treatment – 2.99±0.37 (-52.46 %, р <0.05) and 1.7±0.41 (-60.92 %, р <0.05). In G + Ch group initial data were 7.05±0.43 and 4.85±0.69, after therapy – 3.85±0.35 (-45.39 %, р <0.05) and 2.85±0.51 (-41.24 %, р <0.05). Comparing groups demonstrated the better results according to decrease of WOMAC pain subscale in the group of UC-II: reduce of pain during walking by 28.76 % and reduce of nocturnal pain by 67.65 % (р <0.05).The analysis of the graph of pain during walking has recorded the beginning of significant pain reducing after 30 day of treatment in both groups (Figure 1). The analysis of the graph of nocturnal pain has showed the beginning of significant pain reducing after 50 day of treatment in both groups. Dynamics of nocturnal pain reducing in the G + Ch group was more unstable with periods of reduced efficiency, while in the UC-II group the dynamics was smooth without fluctuations.Figure 1.ConclusionThe therapy of Grade II knee OA with UC-II during 180-day demonstrates the benefit in reducing of pain during walking and nocturnal pain in compare to G + Ch combination. The dynamics of nocturnal pain reducing in the UC-II group characterizes by gradual decline without significant fluctuations.References[1]Bagchi D., Misner B., Bagchi M. et al. (2002) Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int. J. Clin. Pharmacol. Res., 22, 101-10.[2]Robinson W.H., Lepus C.M., Wang Q. et al. (2016) Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol., 12(10), 580-592. doi:10.1038/nrrheum.2016.136.Acknowledgements:NIL.Disclosure of InterestsNone Declared.

APA, Harvard, Vancouver, ISO, and other styles

25

GUPTA, R. C., T. D. CANERDY, P. SKAGGS, et al. "Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses." Journal of Veterinary Pharmacology and Therapeutics 32, no. 6 (2009): 577–84. http://dx.doi.org/10.1111/j.1365-2885.2009.01079.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Bagchi, Manashi, Ramesh C. Gupta, Terry D. Canerdy, John T. Goad, Dale Barnett, and Debasis Bagchi. "Therapeutic efficacy of undenatured type II collagen (UC‐II) in comparison to glucosamine plus chondroitin in arthritic horses." FASEB Journal 22, S2 (2008): 659. http://dx.doi.org/10.1096/fasebj.22.2_supplement.659.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Rui, Fan, Kang Jiawei, Hao Yuntao, et al. "Undenatured type II collagen prevents and treats osteoarthritis and motor function degradation in T2DM patients and db/db mice." Food & Function 12, no. 10 (2021): 4373–91. http://dx.doi.org/10.1039/d0fo03011b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Marone, Palma Ann, Francis C. Lau, Ramesh C. Gupta, Manashi Bagchi, and Debasis Bagchi. "Safety and toxicological evaluation of undenatured type II collagen." Toxicology Mechanisms and Methods 20, no. 4 (2010): 175–89. http://dx.doi.org/10.3109/15376511003646440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Lugo, James P., Zainulabedin M. Saiyed, Francis C. Lau, et al. "Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers." Journal of the International Society of Sports Nutrition 10, no. 1 (2013): 48. http://dx.doi.org/10.1186/1550-2783-10-48.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Gupta, R. C., D. Bagchi, P. Skaggs, et al. "Safety and therapeutic efficacy of undenatured type-ii collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses." Journal of Animal Physiology and Animal Nutrition 93, no. 2 (2009): 142. http://dx.doi.org/10.1111/j.1439-0396.2009.00921_3.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bagchi, Manashi, Ramesh Gupta, J. Lindley, et al. "Suppression of arthritic pain in dogs by undenatured type-II collagen (UC-II) treatment quantitatively assessed by ground force plate." Toxicology Letters 189 (September 2009): S231. http://dx.doi.org/10.1016/j.toxlet.2009.06.495.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Shiojima, Yoshiaki, Megumi Takahashi, Ryohei Takahashi, et al. "Safety of Dietary Undenatured Type II Collagen: A Pilot Open-Label Overdose Clinical Investigation." Functional Foods in Health and Disease 12, no. 3 (2022): 103. http://dx.doi.org/10.31989/ffhd.v12i3.897.

Full text

Abstract:

Background: In advancing age population worldwide, joint discomfort and poor locomotive functions are symptoms, which are often detected. Aggravation of such symptoms potentially develops into osteoarthritis (OA) as characterized by the loss of articular cartilage in the joints of the hand, spine, knee, foot, and hip. For joint health complications, selected functional foods are frequently supplemented orally to alleviate such symptoms. In Japan, Foods with Function Claims (FFC) regulatory system is now positioned within the framework of “so-called health foods” allowing to make functional claims such as brain health and weight control claims. Moreover, a wide variety of knee joint care FFC products are presently available in the marketplace and have attracted much attention of the elderly people, expecting improvements in joint locomotive functions such as walking, sitting, standing, and climbing the stairs for the quality of life (QOL). Supplementation of undenatured type II collagen powder (NEXT-II®) in hard capsules has been clinically proven to improve such joint functions fulfilling part of the FFC rigorous guidelines, while ensuring adequate safety as foods is a crucial prerequisite for filing FFC product dossier.Methods: Twenty-two healthy male and female volunteers (age = 20-74 years) participated in this pilot open-label overdose clinical trial over a period of 4 consecutive weeks. All subjects were also monitored and assessed additional 2 weeks after the completion of the NEXT-II® supplementation period as washout or supplement-free period. Subjects took a 10-fold (10-X) dose of NEXT-II® (400 mg NEXT-II/day containing 32 mg of undenatured type II collagen/day). Daily recommended dose of NEXT-II® is 40 mg/day (containing 3.2 mg of undenatured type II collagen/day) after breakfast. Physical health examination, hematological analysis, blood ,biochemistry examination, and urinalysis were performed. All subjects completed the supplementation of NEXT-II® for 4 weeks and had additional 2 weeks of washout or supplement-free period. All subjects recorded daily diaries. Results: Results demonstrated no significant differences at 0 week (baseline), 2 weeks, and 4 weeks of NEXT-II®supplementation. Furthermore, no significant differences were observed even after 2 weeks of the washout period. No adverse events were observed.Conclusions: Supplementation of 10-fold dose of NEXT-II® to the volunteers was well-tolerated and exhibited the broad-spectrum safety without observing any adverse effects in healthy Japanese subjects.Keywords: Undenatured type II collagen, NEXT-II®, Safety, Overdose supplementation, Clinical study, Foods with Function Claims (FFC)

APA, Harvard, Vancouver, ISO, and other styles

33

Kakatkar, Vijay, A. K. Pal, Raghuveer Reddy, et al. "Adjuvant drugs in management of osteoarthritis: spotlight on type II collagen." International Journal of Research in Orthopaedics 5, no. 4 (2019): 753. http://dx.doi.org/10.18203/issn.2455-4510.intjresorthop20192698.

Full text

Abstract:

Osteoarthritis (OA) is a common musculoskeletal disorder that affects large and small joints and is seen in all ages due to diverse aetiologies. Pain, joint stiffness and limitation of daily activities affects the quality of life of individuals with OA. Conventional analgesics like non-steroidal anti-inflammatory drugs affect pain and inflammatory component but do not target the disease pathogenesis. Damage to the joint cartilage is central to the pathogenesis of OA. Better understanding of the pathogenesis has led to evolution of various adjuvant drugs in management of OA. Among them, undenatured type II collagen induces immune tolerance and thereby provide benefits by reducing the joint damage. Studies assessing efficacy and safety of undenatured type II collagen in OA have shown to reduce clinical symptoms like pain, joint stiffness and improvement in physical activities, and thus improving the quality of life. It is well tolerated and safe for use in OA. This article discusses the pathophysiology of OA with inflammation and beyond, and overviews the various drugs that are used as adjuvants in the management of OA with special focus on the use of type 2 collagen.

APA, Harvard, Vancouver, ISO, and other styles

34

Yoshinari, Orie, Yoshiaki Shiojima, Hiroyoshi Moriyama, et al. "Water-Soluble Undenatured Type II Collagen Ameliorates Collagen-Induced Arthritis in Mice." Journal of Medicinal Food 16, no. 11 (2013): 1039–45. http://dx.doi.org/10.1089/jmf.2013.2911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Xu, Rong, Jianping Wu, Lin Zheng, and Mouming Zhao. "Undenatured type II collagen and its role in improving osteoarthritis." Ageing Research Reviews 91 (November 2023): 102080. http://dx.doi.org/10.1016/j.arr.2023.102080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Fan, Rui, Yuntao Hao, Xinran Liu, et al. "Correction: Fan et al. Native Collagen II Relieves Bone Impairment through Improving Inflammation and Oxidative Stress in Ageing db/db Mice. Molecules 2021, 26, 4942." Molecules 27, no. 2 (2022): 571. http://dx.doi.org/10.3390/molecules27020571.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Yoshinari, Orie, Hiroyoshi Moriyama, and Yoshiaki Shiojima. "An Overview of a Novel, Water-Soluble Undenatured Type II Collagen (NEXT-II)." Journal of the American College of Nutrition 34, no. 3 (2015): 255–62. http://dx.doi.org/10.1080/07315724.2014.919541.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Yoshinari, Orie, Hiroyoshi Moriyama, Yoshiaki Shiojima, and Hiromi Miyawaki. "Evaluation of Efficacy and Safety of NEXT-II®, a Novel Water-Soluble, Undenatured Type II Collagen in Subjects with Potential Risks in the Knee Joint Health from Healthy Population." Functional Foods in Health and Disease 5, no. 7 (2015): 251. http://dx.doi.org/10.31989/ffhd.v5i7.187.

Full text

Abstract:

Background: Oral administration of a novel water-soluble undenatured type II collagen (NEXT-II®) has been demonstrated to ameliorate the signs and symptoms of rheumatoid arthritis (RA) in animal models. In the present investigation, we conducted a pilot study to examine the efficacy and safety of NEXT-II® in borderline subjects defined as healthy and non-diseased state, but with potential risks in knee joint health. Method: We employed Western Ontario McMaster Index (WOMAC) score and Visual Analog Scale (VAS) scores to assess the extent of improvement in the knee joints in these volunteers following supplementation of 40 mg NEXT-II® (10 mg as undenatured type II collagen) over a period of 12 weeks. Result: The results demonstrated that NEXT-II® treatment significantly reduced WOMAC and VAS scores compared to subjects at baseline. Specifically, in the evaluation using VAS, the borderline subjects at resting, walking, and going up and down the stairs revealed significant improvement when compared to the baseline. Conclusion: The results of the studies demonstrated that NEXT-II® might be an ingredient which is safe and effective in the application of dietary supplement in ameliorating joint pain and symptoms of the borderline subjects without any adverse events.

APA, Harvard, Vancouver, ISO, and other styles

39

Chen, Nan-Fu, Yen-You Lin, Zhi-Kang Yao, et al. "Oral Administration of Protease-Soluble Chicken Type II Collagen Ameliorates Anterior Cruciate Ligament Transection–Induced Osteoarthritis in Rats." Nutrients 15, no. 16 (2023): 3589. http://dx.doi.org/10.3390/nu15163589.

Full text

Abstract:

This study investigated whether oral supplementation with protease-soluble chicken type II collagen (PSCC-II) mitigates the progression of anterior cruciate ligament transection (ACLT)–induced osteoarthritis (OA) in rats. Eight-week-old male Wistar rats were randomly assigned to the following groups: control, sham, ACLT, group A (ACLT + pepsin-soluble collagen type II collagen (C-II) with type I collagen), group B (ACLT + Amano M–soluble C-II with type I collagen), group C (ACLT + high-dose Amano M–soluble C-II with type I collagen), and group D (ACLT + unproteolyzed C-II). Various methods were employed to analyze the knee joint: nociceptive tests, microcomputed tomography, histopathology, and immunohistochemistry. Rats treated with any form of C-II had significant reductions in pain sensitivity and cartilage degradation. Groups that received PSCC-II treatment effectively mitigated the ACLT-induced effects of OA concerning cancellous bone volume, trabecular number, and trabecular separation compared with the ACLT alone group. Furthermore, PSCC-II and unproteolyzed C-II suppressed ACLT-induced effects, such as the downregulation of C-II and upregulation of matrix metalloproteinase-13, tumor necrosis factor-α, and interleukin-1β. These results indicate that PSCC-II treatment retains the protective effects of traditional undenatured C-II and provide superior benefits for OA management. These benefits encompass pain relief, anti-inflammatory effects, and the protection of cartilage and cancellous bone.

APA, Harvard, Vancouver, ISO, and other styles

40

Azeem, Mohammed Abdul. "The Study of undenatured type II collagen in the knee osteoarthri." International Journal of Orthopaedics Traumatology & Surgical Sciences 5, no. 1 (2019): 172–75. http://dx.doi.org/10.47618/ijotss/v5i1.39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Gromova, O. A., I. Yu Torshin, and A. M. Lila. "Molecular Mechanisms of Action of Undenatured Type II Collagen: Experimental and Clinical Evidence." Modern Rheumatology Journal 16, no. 5 (2022): 108–13. http://dx.doi.org/10.14412/1996-7012-2022-5-108-113.

Full text

Abstract:

In the treatment of joint diseases, including osteoarthritis (OA), the use of standardized extracts of undenatured type II collagen (UDC-II) is promising. It is known that UDC-II is involved in the regulation of innate and adaptive immunity (reduction of autoimmune reactions that stimulate cartilage degradation) and in the reduction of chronic inflammation activity (modulation of cytokines and prostaglandins). The effect of UDC-II on discoidin receptors of chondrocytes helps to prevent structural disorders of the cartilage connective tissue. Experimental and clinical studies have shown that under the influence of standardized UDC-II, there is an increase in the proportion of regulatory CD4+ T cells, a decrease in the levels of pro-inflammatory cytokines, such as interleukin (IL) 1β, IL6, tumor necrosis factor α, CRP, prostaglandins in the blood, as well as matrix metalloproteinase 3 and NF-κB expression in cartilage. The use of UDC-II in OA leads to a significant reduction in pain, an increase in the range of joint motion, an improvement in joint function according to WOMAC and quality of life.

APA, Harvard, Vancouver, ISO, and other styles

42

PEAL, A., M. D'ALTILIO, C. SIMMS, et al. "Therapeutic efficacy and safety of undenatured type-II collagen (UC-II) alone or in combination with (?)-hydroxycitric acid and chromemate in arthritic dogs." Journal of Veterinary Pharmacology and Therapeutics 30, no. 3 (2007): 275–78. http://dx.doi.org/10.1111/j.1365-2885.2007.00844.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Bagi, C. M., E. R. Berryman, S. Teo, and N. E. Lane. "Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA)." Osteoarthritis and Cartilage 25, no. 12 (2017): 2080–90. http://dx.doi.org/10.1016/j.joca.2017.08.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Shavlovskaya, O. A., O. A. Gromova, and I. Yu Torshin. "Points of undenatured type II collagen application in musculoskeletal pain syndromes treatment." Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122, no. 11 (2022): 40. http://dx.doi.org/10.17116/jnevro202212211140.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Mehra, Apurv, Pankaj Anand, Mangesh Borate, et al. "A non-interventional, prospective, multicentric real life Indian study to assess safety and effectiveness of un-denatured type 2 collagen in management of osteoarthritis." International Journal of Research in Orthopaedics 5, no. 2 (2019): 315. http://dx.doi.org/10.18203/issn.2455-4510.intjresorthop20190798.

Full text

Abstract:

Background: Osteoarthritis (OA) is the most common musculoskeletal conditions affecting the quality of life. Undenatured collagen type II has emerged as one of the promising treatment options in treatment of OA. Despite being available in India, clinical safety and efficacy have not been evaluated. We performed a non-interventional, real-life study to determine its safety and efficacy in Indian population.Methods: A non-interventional, real-life study was performed in patients with OA of knee by 18 orthopaedicians in India. Patients enrolled were followed-up at day 30 (visit 2), day 60 (visit 3) and day 90 (visit 4). Efficacy was assessed by Western Ontario McMaster Osteoarthritis Index (WOMAC) and Visual Analogue scale (VAS) on each visit. Safety was assessed by incidence of suspected adverse events (AEs), and abnormal laboratory parameters.Results: Among 291 enrolled patients 226 patients completed the study. Mean age of the population was 56.2±8.7 years and 53.3% of them were females. In 291 patients included in safety analysis, at least one treatment emergent adverse event (TEAE) was seen in 4.47% patients. None of the AEs were serious or resulted in termination of patient from the study. Nausea (1.37%) and headache (1.03%) were the common AEs. Treatment with undenatured collagen type II was associated with significant reduction in WOMC score (p&lt;0.0001) and VAS scores (p&lt;0.0001) from baseline to day 90.Conclusions: Undenatured collagen type II is safe and efficacious in Indian patients with OA. This can be considered early in the initial management of OA.

APA, Harvard, Vancouver, ISO, and other styles

46

Yoshinari, Orie, Palma Ann Marone, Hiroyoshi Moriyama, Manashi Bagchi, and Yoshiaki Shiojima. "Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen." Toxicology Mechanisms and Methods 23, no. 7 (2013): 491–99. http://dx.doi.org/10.3109/15376516.2013.781255.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Rekalov, D., I. Golovach, and I. Daniuk. "Score Assessment Of Efectiveness Of Knee Osteoarthritis Treatment With Undenatured Collagen Type II." Osteoarthritis and Cartilage 31 (March 2023): S411. http://dx.doi.org/10.1016/j.joca.2023.01.478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Cabezas, Miguel, Javier Benito, Alvaro Ortega, and Elena Pedraza. "Long-term supplementation with an undenatured type-II collagen (UC-II"&#".ord($0).";""&#".ord($0).";") formulation in dogs with degenerative joint disease: exploratory study." Open Veterinary Journal 12, no. 1 (2022): 91. http://dx.doi.org/10.5455/ovj.2022.v12.i1.11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Dydykina, I. S., P. S. Kovalenko, A. A. Kovalenko, and A. V. Aboleshina. "The value of undenatured collagen for the normalization of the function of the cartilaginous tissue of the joints." Meditsinskiy sovet = Medical Council, no. 14 (August 12, 2022): 145–53. http://dx.doi.org/10.21518/2079-701x-2022-16-14-145-153.

Full text

Abstract:

Among the proteins of the human body, collagen accounts for at least 25–45% collagen; it is an essential structural component of skeletal tissues, connective tissue of internal organs (heart, intestines, lungs, liver, kidneys), as well as blood vessels. The variety of types of collagen is due to their role and function. The article presents information about the structure and synthesis of collagen, a high concentration of glycine, proline and hydroxyproline in the alpha chains of the collagen helix. Attention is drawn to the fact that cross-links and orientation of collagen fibers in the direction of the vector of external forces and loads provide protection to tissues and organs. The clinical significance of type II collagen is considered on the example of the cartilaginous tissue of the joints and tendons. It is emphasized that an imbalance in the structure of nutrition, genetic mutations, dysfunction of the endocrine and immune systems, especially in old age, are associated with the occurrence of one of the most common joint diseases – osteoarthritis (ОА). It has been established that the degradation or reduction of type II collagen in the cartilage matrix is accompanied by the progression of this disease. Due to the increasing prevalence of OA, signs of metabolic disorders and post-traumatic joint injuries, there is a growing interest in non-pharmacological and pharmacological interventions for the prevention and treatment of osteoarthritis. In recent years, convincing evidence has emerged of the successful use of drugs (biologically active food supplements) of collagen in osteoarthritis. The article presents the results of experimental and clinical studies, meta-analysis and systematic review, confirming the possibility of using these drugs (products) as part of the complex treatment of OA. The possibility of using compositions based on undenatured (native) collagen type II, with the inclusion of ascorbic acid, vitamin D, methylsulfonylmethane and boswellic acids promotes the synergy of these substances, slows down the rate of cartilage destruction, reduces the manifestation of pain and inflammation in the joints, improves functional joint and spinal conditions, promotes the synthesis of endogenous collagen.

APA, Harvard, Vancouver, ISO, and other styles

50

Babu, Dr Sathik, Dr Pradeep Elangovan, and Dr Dinesh Kumar S. "Role of undenatured collagen type ii in management of osteoarthritis: A hospital based study." International Journal of Orthopaedics Sciences 6, no. 4 (2020): 747–50. http://dx.doi.org/10.22271/ortho.2020.v6.i4k.2414.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Undenatured type II collagen (UC-II)'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles